However, it was unclear whether SCN+ patients could benefit from CCRT because the proportion of SCN+ patients was not reported in most randomized controlled studies for CCRT in stage III NSCLC patients [10, 11]. The gene discussed is SRI; the disease is non-small cell lung carcinoma.